May 15, 2024 4:01 pm EDT Eyenovia Reports First Quarter 2024 Financial Results and Provides Updates on its Myopia Phase III Program and its Two FDA Approved Commercial Products, Mydcombi and Clobetasol
Apr 25, 2024 7:00 am EDT Eyenovia Provides Clinical and Scientific Update on FDA-Approved Products Mydcombi™ and Clobetasol Propionate Ophthalmic Suspension
Apr 8, 2024 7:00 am EDT Eyenovia Announces Updated Strategy and Corporate Priorities to Focus on Shareholder Value Generation and Immediate Commercial Opportunities
Apr 3, 2024 7:00 am EDT Eyenovia to Feature its Suite of Commercial Products and the Optejet Dispenser at Upcoming National Eyecare Meetings
Mar 18, 2024 4:05 pm EDT Eyenovia Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
Mar 13, 2024 7:00 am EDT NovaBay Pharmaceuticals and Eyenovia to Co-Promote Prescription Ophthalmic Products to U.S. Eyecare Professionals
Mar 11, 2024 7:00 am EDT Eyenovia to Report Fourth Quarter 2023 Results and Provide Business Update on Monday, March 18th
Mar 5, 2024 8:00 am EST Eyenovia Congratulates Formosa Pharmaceuticals on FDA Approval of Clobetasol Propionate Ophthalmic Suspension 0.05% for the Treatment of Post-operative Inflammation and Pain Following Ocular Surgery